Segall Bryant & Hamill’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Segall Bryant & Hamill’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-7,207	Closed	-$389K	–	633
2017 Q4	$389K	Sell	7,207 -243	-3%	-$13.3K	0.01%	458
2017 Q3	$425K	Sell	7,450 -300	-4%	-$17.6K	0.01%	445
2017 Q2	$466K	Sell	7,750 -174	-2%	-$9.91K	0.01%	437
2017 Q1	$432K	Buy	+7,924	New	+$390K	0.01%	426

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Segall Bryant & Hamill's BIVV Position: Q1 2018 in Review

Segall Bryant & Hamill sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 7,207 shares — an estimated $389K sold.

Segall Bryant & Hamill first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $466K in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Segall Bryant & Hamill reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Segall Bryant & Hamill sold 7,207 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $389K.
Segall Bryant & Hamill first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Segall Bryant & Hamill's Bioverativ Inc. Common Stock position peaked at $466K in Q2 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Segall Bryant & Hamill's 13F filing for Q1 2018, filed 16 May 2018.